التفاصيل البيبلوغرافية
| العنوان: |
High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study. |
| المؤلفون: |
Cordova-Delgado, Miguel, Pinto, Mauricio P., Retamal, Ignacio N., Muñoz-Medel, Matías, Bravo, María Loreto, Fernández, María F., Cisternas, Betzabé, Mondaca, Sebastián, Sanchez, César, Galindo, Hector, Nervi, Bruno, Ibáñez, Carolina, Acevedo, Francisco, Madrid, Jorge, Peña, José, Koch, Erica, Maturana, Maria José, Romero, Diego, de la Jara, Nathaly, Torres, Javiera |
| المصدر: |
Cancers; Sep2019, Vol. 11 Issue 9, p1275-1275, 1p |
| مصطلحات موضوعية: |
CANCER patients, EPSTEIN-Barr virus, IMMUNOTHERAPY, MORTALITY, ONCOGENES, STATISTICS, STOMACH tumors, TRANSFERASES, TISSUE arrays, GENE expression profiling, DESCRIPTIVE statistics |
| مصطلحات جغرافية: |
CHILE |
| مستخلص: |
Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular profile of Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples and clinical data were obtained from 224 patients, with subsets analyzed by tissue microarray (TMA; n = 90) and next generation sequencing (NGS; n = 101). Most demographic and clinical data were in line with previous reports. TMA data indicated that 60% of patients displayed potentially actionable alterations. Furthermore, 20.5% were categorized as having a high tumor mutational burden, and 13% possessed micro-satellite instability (MSI). Results also confirmed previous studies reporting high Epstein-Barr virus (EBV) positivity (13%) in Chilean-derived GC samples suggesting a high proportion of patients could benefit from immunotherapy. As expected, TP53 and PIK3CA were the most frequently altered genes. However, NGS demonstrated the presence of TP53, NRAS, and BRAF variants previously unreported in current GC databases. Finally, using the Kendall method, we report a significant correlation between EBV+ status and programmed death ligand-1 (PDL1)+ and an inverse correlation between p53 mutational status and MSI. Our results suggest that in this Chilean cohort, a high proportion of patients are potential candidates for immunotherapy treatment. To the best of our knowledge, this study is the first in South America to assess the prevalence of actionable targets and to examine a molecular profile of GC patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder